Enterprising early career researchers get some high-level mentoring to handle the rough and tumble of the boardroom. David Payne meets finalists in the 21st annual Young Entrepreneurs Scheme (YES)
Epitome is a Singapore biotech start-up whose product pipeline is based on engineered tail proteins to tackle bacterial diseases. It wants a slice of the US’s $6bn acne market. Epitome’s founders are seeking raise $10m to build a factory where its cosmetic products can be manufactured. Investors will be rewarded with a seat on its board.
The launch team describe the company at a presentation attended by other young entrepreneurs. They brace themselves for some tough questions from a judging panel. One judge asks how a factory can be built for $10m Another challenges the team’s plan to launch an acne treatment as a cosmetic product, which means they won’t mention acne on the label (the team adopted this approach to make the US regulatory process more straightforward).
Elena Lurieluke, Head of Global Life Sciences Open Innovation, Corporate R&D at P&G, addresses fellow YES judges and finalists.
